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Background. There is limited information on the eﬀectiveness of meal replacements (MRs) as a weight-loss strategy in an
unsupervised community setting. Aim. To evaluate the use of MR compared with a diet book for 6 months. Subjects and Methods.
Obese subjects (n = 120) with type 2 diabetes mellitus were recruited from the community in Adelaide, South Australia, and
randomised to intervention or control. Subjects in the intervention were advised to consume 2MR/day for 3months and 1MR/day
for 3 months and follow the manufacturers’ instructions from printed material and the website. Subjects in the control arm were
given a commercially available diet book. Results. Consumption of 2 MR for 3 months and 1 MR for the subsequent 3 months led
to weight loss of 5.5 kg (5%) and a 0.26% decrease in HbA1c while the diet book group had a weight loss of 3 kg (3%) (P = 0.027
for diﬀerence between groups) and a decrease in HbA1c of 0.15% (between group ns) in those who completed the 6-month study.
On intention-to-treat (last observation carried forward) weight loss at 6 months was 3.4 kg inMR and 1.8 kg in control (P = 0.07).
Decreases in HbA1c were 0.22% and 0.12%, respectively (P = ns). HDL cholesterol increased by 4% inMR and decreased by 1% in
control (P = 0.004). Blood pressure decreased equally in both groups. There were reductions in fasting glucose in both groups at 6
months with no changes in LDL-cholesterol or triglyceride concentrations. Conclusion. MR confers benefits in HbA1C reduction
and weight loss at 6 months in those who completed the study.
1. Background
Cardiovascular disease and type 2 diabetes are strongly
associated with obesity and there is very good evidence that
weight loss lowers glucose, blood pressure, LDL cholesterol,
and triglyceride [1]. The incidence of obesity in Australia and
other developed countries is increasing with a subsequent
swell of public interest in dietary strategies to reduce
body weight [2]. Formulated meal replacements designed
for weight loss represent a possible strategy for some
individuals [3]. There is little evidence that this approach
is eﬀective when used without professional support nor is
there evidence for how it compares to conventional dietary
approaches used in the same context. In previous studies we
have demonstrated that meal replacement provided excellent
results that were not diﬀerent to professional dietary advice
at 3 and 6 months in overweight and obese subjects with
an elevated triglyceride level [4]. We have also shown that
high protein meal replacements can be very eﬀective in long
term in nondiabetic subjects and although we did not have
a control group in this study the meal replacements would
certainly be better than advice alone [3]. Meal replacements
are being used in the Look Ahead Diabetes study in the USA
as part of a comprehensive behavioural strategy and at 12
months a weight loss of 8.6% versus 0.8% in the control
group had occurred [5] which had reduced to 4.7% and 1.1%
at 4 years [6].
Other than the Wisconsin community study [7] most
meal replacement trials have used either dietitian, physician,
or nurse input in addition to information supplied with the
meal replacements. However in practice most meal replace-
ment products would be consumed without the assistance
of dietitian input and feedback as they are freely available
for purchase in community pharmacies and supermarkets.
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Our aims were to evaluate, under field conditions, a weight
loss strategy of a meal replacement product compared with
no treatment for 6 months. Our hypotheses were that the
meal replacements would lead to a weight loss of 8–10 kg at
12 weeks which would be maintained at 6 months and would
produce greater HbA1c lowering compared with standard
dietary advice provided using a commercially available diet
book.
2. Subjects and Methods
One hundred and twenty overweight and obese subjects
with type 2 diabetes mellitus were recruited from the Com-
monwealth Scientific and Industrial Research Organisation
(CSIRO) database. Inclusion criteria were type 2 diabetes
(HbA1c 6.5–12%), age 20–65 years, not greater than 140 kg
(exceeded scale limit), with no abnormality of clinical
significance on medical history and if female, not pregnant
or breast feeding. Subjects had to understand the procedures
involved and agree to participate in the study by giving
full informed, written consent. All medication was allowable
including insulin. Exclusion criteria were type 1 diabetes
(by history only), history of heavy alcohol consumption
(>5 STD drinks/day) and participant unable to cease alcohol
consumption for study duration, widely fluctuating exercise
patterns, frequent dining out (>2x/week) and unable to
cease, inability to prepare meals or meet diet requirements,
extended absences due to travel or other commitments or
unable to comprehend or cope with study requirements.
The following items if taken had to be kept stable
during the study: prednisolone, cholesterol lowering agents,
antihypertensive agents, and fish oil supplements.
2.1. Study Design. Following screening and selection from
the CSIRO volunteer database, subjects were randomised
into two groups: meal replacement (MR) or diet book
control (DB) with 60 subjects in each group matched for age,
sex, and BMI using the Clinstat randomisation program. The
authors were blinded to treatment allocation until after the
statistical analysis was performed. Subjects then commenced
a 24-week active weight loss phase. The meal replacement
group consumed 2 meal replacements (880 kilojoules each)
and a low fat evening meal per day with at least 5 serves of
fruit and vegetables/day (total approximately 5000 kJ). Meal
replacements were provided at the CSIRO clinic at no charge
every 4 weeks. All subjects were weighed every 4 weeks. Meal
replacements Probiotec Formula WL (Probiotec Limited,
Laverton North, VIC, Australia 3026) were used. The meal
replacement group was given all the product material and
access to the website. No dietary information was sought
other than compliance to use of the meal replacement with
a daily checklist.
The control group were given the CSIRO Total Wellbeing
Diet Book and were given no verbal advice. Vouchers to
the value of the MRs were provided every 4 weeks. Control
subjects were weighed at the same frequency as the meal
replacement group. The study was approved by the CSIRO
Food and Nutritional Sciences Human Ethics Committee
and written, informed consent was obtained. A CONSORT
statement is shown in Figure 1.
2.2. Measurements. Body weight was measured using an
electronic digital scales (Mercury, AMZ14, Tokyo, Japan).
Body composition (total fat mass (FM) and total fat freemass
(FFM)) was measured using dual-energy X-ray absorptiom-
etry (Lunar Prodigy; General Electric Corporation, Madison,
WI, USA). Seated blood pressure was measured, after
5 minutes rest, using an automated sphygmomanometer
(DINAMAP 8100, Criticon, Tampa, FL, USA).
2.3. Biochemistry. Plasma glucose, and serum lipids and
insulin were measured using standard commercial assay
kits as published previously [8]. HbA1c was measured
using high-performance liquid chromatography at a certified
commercial laboratory (Pathology SA, Adelaide, SA).
2.4. Statistical Analysis. Statistical analysis was performed
using PASW for Windows (version 18.0, SPSS, Chicago, IL,
USA). One-way analysis of variance (ANOVA) was used to
compare between-group diﬀerences at baseline. The eﬀects
of time and group were assessed using repeated measures
ANOVA with time as the within-subject factor and group as
between-subject factor. A completers analysis was performed
and there was also an intention to treat analysis for weight
and HbA1c. Statistical significance was set at P ≤ 0.05. Data
are presented as means ± standard deviation.
2.5. Power. We had enough power (80%, alpha 0.05) to
detect a diﬀerence from control of 2 kg in weight, and a
diﬀerence in LDL cholesterol of 0.2mmol/L and a diﬀerence
in HbA1c of 0.3%.
3. Results
3.1. Subjects. Forty three subjects (16 women, 27 men) MR
subjects and 38 (15 women, 23 men) DB subjects completed
6-months. Baseline characteristics of those enrolled and the
6 months completers are shown in Table 1. Those who
dropped out had a significantly greater BMI (36 kg/m2) than
those who completed 6 months (33.7 kg/m2) (P = 0.021).
3.2. Weight. Weight of the subjects who completed 3 months
of the study is shown in Table 2. Weight loss at 3 months
was 5.5 kg versus 3.0 kg and at 6 months was 5.0 kg versus
3.0 kg in the 6-month completers group. This is very similar
to the whole group at 3 months where the weight loss
was 5.3 kg versus 2.7 kg (Table 3, P = 0.01, n = 87).
The overall eﬀect of both diets was significant (time P =
0.001) with a diet by time interaction of P = 0.016.
The change in weight was significantly diﬀerent between
treatments at both 3 months (P = 0.001) and 6 months (P =
0.027). The change in weight was not predicted by age, sex,
BMI, alcohol consumption, smoking, exercise pattern, nor
postmenopausal status. Within the MR group the number
of meal replacements consumed and initial BMI predicted
the weight change at 6 months and accounted for 25% of
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Assessed for eligibility (n = 115) from
computerised history
Analysed (n = 43)
♦ Excluded from analysis (n = 0)
Lost to follow-up (n = 2)
Discontinued intervention (n = 10), dislike of
MR (2), time (4), doctors advice (2)
Lost to follow-up (n = 2)
Discontinued intervention (n = 10), dislike of
diet (5), medical (3), time (2)
Allocated to intervention (n = 55)
♦ Received allocated intervention (n = 47)
♦ Did not receive allocated intervention
(n = 8), medical (2), HbA1c high (1), no
reason given (5)
Analysed (n = 38)
♦ Excluded from analysis (n = 0)
Randomised (n = 115)
Allocated to intervention (n = 60)
♦ Received allocated intervention (n = 54)
♦ Did not receive allocated intervention (n = 6). Time
(3), dislike of MR (3)
Figure 1: CONSORT flow diagram.
the variance (P = 0.03). This also applied at 3 months and
accounted for 32% of the variance (P = 0.002). Within the
DB group gender was associated with weight loss with men
losing more weight than women at 3 months (P = 0.029) but
not at 6 months.
On intention to treat analysis with last observation
carried forward weight loss at 3 months was 4.0 ± 3.8 kg in
the MR group versus 2.3± 2.3 kg in the DB group (P < 0.01)
while at 6 months the weight loss was 3.4 ± 5.2 kg versus
1.8± 3.4 kg (P = 0.07).
3.3. Body Composition. Body composition is shown in
Table 4. Bone mineral density BMD (P < 0.001) but not
bonemineral content (total bonemass, bonemineral content
(BMC)) changed with time with no diﬀerences between
treatments. Fat mass and lean mass changed with time (P <
0.001) with a treatment interaction with fat mass (P =
0.04) such that fat mass fell more with MR (3.0 kg versus
1.3 kg). The change in fat mass was greater in MR in the legs
(peripheral fat) (0.7 kg versus 0.0 kg at 6 months, P < 0.05)
rather than the trunk (central fat) where the fat loss was
not statistically diﬀerent despite a diﬀerence of 2.1 kg versus
1.3 kg. In the android region the total fat (P = 0.051) and the
fat/lean ratio was diﬀerent between treatments falling 10%
with MR and with no change in DB (P = 0.035). Smokers
had enhanced the lean loss in the android region. There were
no diﬀerences in the gynoid region.
On linear regression predictors of total fat change were
postmenopausal status (negatively), HRT (positively), and
exercise (positively), accounting for 16% of the variance in
fat change (P = 0.013). For the 3-month fat change treat-
ment also played a role along with HRT and postmenopausal
status, accounting for 21% of the variance, P = 0.001. Lean
mass loss at 6 months was directly related to starting weight
and smoking (10% of variance, P = 0.015). At 3 months lean
loss was higher in women and related to baseline lean mass.
3.4. HbA1c. Blood tests for HbA1c at 6 months were ob-
tained from 40 onMR and 34 on DB. Overall (using baseline,
3 months and 6 months) there was an eﬀect of time
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Table 1: Baseline characteristics of subjects enrolled and subjects






Age (yr) 60.9 61.7
Women/men 49/66 30/50
Height (m) 1.71 1.71
Weight (kg) 100.8 100.7
BMI (kg/m2) 34.4 33.7∗
HbA1c (%) 6.9 6.8
Alcohol consumers (%) 53 54
Smokers (%) 7 6




Insulin (%) 14 8
1 drug (%) 37 22
2 drugs (%) 41 27
3 drugs (%) 9 5







Data are mean ± SD.
∗P < 0.05.
Table 2: Subjects who completed 3 months.
Weight (kg) Baseline 3 months
Treatment MR DB MR DB
Mean ± SD 103.3± 16.6 99.7± 16.5 98.0± 16.5 /= 96.5± 17.0
Data are mean ± SD.
MR: n = 47, DB: n = 40.
/=P < 0.01 time by diet interaction.
(P = 0.035) and there was a diet by time interaction (P =
0.021) (Table 5). The change in HBA1c at 3 months was
0.49% for MR and 0% for DB (P = 0.015 for diet by time
interaction) and at 6 months was 0.26% for MR and 0.15%
for DB (P = 0.5 for diet by time interaction). There were
reductions of drug dose in 6 volunteers in the MR group (5
of whom had falls in HbA1c at 6 months) and 2 reductions
and 2 increases in the DB (which lead to further drops in
HbA1c of 0.6% and 1% in these volunteers). Overall time
(P < 0.001) treatment (P = 0.018) and dosage change
(P = 0.015) were significant. Statistically dosage change had
a very strong eﬀect on HbA1c at 3 months which is when
most of the changes occurred (treatment P = 0.001, dosage
change P = 0.006, interaction P = 0.003) and a weaker eﬀect
at 6 months (treatment P = 0.06, dosage change P = 0.026,
interaction P = 0.054). Those who had a dosage change at
6 months on MR had a fall in HbA1c of 1.2% (n = 6),
which clearly would have been greater if the reduction had
not occurred while those who had a dosage change on the
diet book only had a change in HbA1c of 0.2% (n = 4).
There was a reduction in the amount of insulin in 3 people
on MR (1 stopped altogether) and there were 3 reductions
in oral medication in the MR group. In the book group
there was one reduction in insulin dosage and 1 reduction
in medication dosage and 2 alterations in medication type.
For the change in HbA1c at 6 months both screening
HbA1c and change in weight at 6 months together predicted
21% of the change in HbA1c (P = 0.001) while for the
change in HbA1c at 3 months change in medication and
treatment and screening HbA1c accounted for 25% of the
variance (P = 0.001).
On intention to treat analysis with last observation
carried forward fall in HbA1c at 3 months was 0.40± 0.83%
in the MR group versus 0 ± 0.71% in DB (P < 0.01) while
at 6 months the fall was 0.22 ± 0.74% versus 0.12 ± 0.66%
(P = 0.5).
3.5. Lipids and Glucose. Cholesterol (P = 0.012), triglyceride
(P = 0.0310), and glucose (P = 0.002) concentrations
changed with both diets at 3 months and there were time by
treatment interactions for HDL cholesterol only (P = 0.004)
with rises in HDL for MR and fall in HDL for diet book.
HDL cholesterol was significantly lower at all time points in
the MR group (Table 6). At 6 months only glucose was lower
than at baseline in both diets and there was a medication
change (P = 0.014) interaction (Table 7).
3.6. Blood Pressure. Both systolic blood pressure (SBP) and
diastolic blood pressure (DBP) decreased significantly with
time (SBP 129± 14 to 124± 13 to 128± 13mmHg at 3 and 6
months, resp., n = 77, P < 0.001, DBP 76 ± 10 to 71 ± 9 to
73 ± 9mmHg at 3 and 6 months, resp., n = 77, P < 0.001),
but there was no eﬀect of treatment type.
4. Discussion
The main finding of the study, that set out to mirror a real
world setting where individuals buy meal replacements from
a supermarket or pharmacy, was that consumption of 2 meal
replacements for 3 months and 1 meal replacement for a
further 3 months led to greater weight loss of approximately
2 kg (5%) and a 0.11% decrease in HbA1c compared with
control subjects who used a commercially available weight
loss book. However on intention to treat analysis which
reflects real world use of the meal replacements with many
people discontinuing treatment by 6 months there was no
diﬀerence seen in either weight or HbA1c compared with the
weight loss book. If the meal replacements were purchased
rather than provided, then drop out rates may have been
even higher. There were no benefits on LDL cholesterol or
triglyceride but HDL cholesterol was increased compared
with the diet book group. Fasting triglyceride was not
abnormal to begin with and the 5% weight loss was too
low to alter it significantly. Fasting glucose was decreased
to a small degree in both groups reflecting reduced food
intake. The overall weight loss in the meal replacement group
of 5.5 kg in those who completed the study is clinically
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Table 3: Subjects who completed 6 months.
Weight (kg) Baseline 3 months 6 months
Treatment MR DB MR DB MR DB
mean ± SD 102.4± 15.4 98.8± 16.7 96.9± 15.3 /= 95.7± 16.9 97.45± 15.94∗ 95.8± 17.1
Data are mean ± SD.
MR: n = 43, DB: n = 37.
/=P < 0.01 time by diet interaction.
∗P < 0.05 time by diet interaction.
Table 4: Bone density, bone mineral content, fat and lean mass, by dual X-ray absorptiometry at baseline 3 and 6 months in subjects who
completed the study.
Baseline 3 months 6 months
MR DB MR DB MR DB
BMD 1.34± 0.10 1.34± 0.12 1.32± 0.10 1.31± 0.12 1.34± 0.10 1.34± 0.12
BMC 3.38± 0.58 3.34± 0.66 3.37± 0.56 3.35± 0.65 3.37± 0.55 3.34± 0.67
Fat mass (kg) 38.9± 8.5 35.6± 9.8 35.5± 8.6∗ 33.8± 9.7 35.9± 9.2∗ 34.3± 9.9
Lean mass (kg) 58.6± 11.9 57.1± 9.6 57.2± 11.8 55.8± 9.8 57.3± 11.8 55.9± 8.9
Data are mean ± SD.
MR: n = 40, DB: n = 34, ∗P < 0.01 time by diet interaction.
Table 5: HbA1c.
Baseline 3 months 6 months
MR DB MR DB MR DB
7.3± 1.0% 7.1± 1.0% 6.8± 0.8%∗ 7.0± 1.1% 7.0± 1.0% 6.9± 0.9%
Data are mean ± SD.
MR: n = 40, DB: n = 34.
∗P < 0.05 time by diet interaction at 3 months.
Table 6: Lipids and glucose at baseline and 3 months.
Baseline 3 months
MR DB MR DB
Total cholesterol (mmol/L)∗ 4.12± 1.12 4.22± 0.86 3.98± 1.06 4.06± 0.86
Triglycerides∗ 1.56± 0.50 1.57± 0.81 1.36± 0.58 1.48± 0.64
HDL cholesterol (mmol/L) 1.05± 0.23 1.20± 0.30 1.09± 0.29 1.15± 0.29
LDL cholesterol (mmol/L)∗ 2.36± 0.99 2.34± 0.80 2.28± 0.97 2.23± 0.77
Glucose (mmol/L)∗ 7.80± 1.63 7.65± 1.46 7.24± 1.49 7.33± 1.73
Data are mean ± SD.
MR: n = 47, DB: n = 40.
∗P < 0.05 main eﬀect of time.
Table 7: Lipids and glucose at baseline and 6 months.
Baseline 6 months
MR DB MR DB
Total cholesterol (mmol/L) 4.10± 1.15 4.20± 0.87 4.31± 1.15 4.18± 0.89
Triglyceride (mmol/L) 1.56± 0.54 1.57± 0.84 1.66± 0.75 1.58± 0.79
HDL cholesterol (mmol/L) 1.05± 0.22 1.22± 0.30 1.09± 0.26 1.21± 0.31
LDL cholesterol (mmol/L) 2.34± 1.01 2.30± 0.82 2.46± 0.99 2.25± 0.72
Glucose (mmol/L)∗ 7.85± 1.70 7.66± 1.52 7.48± 2.02 7.08± 1.30
Data are mean ± SD.
MR: n = 40, DB: n = 35.
∗P < 0.05 main eﬀect of time.
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significant as is the fall in HbA1c of 0.3% from baseline and
the changes are comparable to those seen in other studies [9–
14].
Meal replacements are used as a weight loss strategy
in people with and without type 2 diabetes and have
become a strategy of choice when substantial weight loss is
needed [9–11]. In a systematic review of controlled trials
of lifestyle interventions Brown et al. observed that when
meal replacements were added to a low-fat diet there was
a significant improvement in weight loss of 5.4 kg [10]. In
people with diabetes meal replacements are most often used
as part of a multidisciplinary weight management program
as they are a viable and potentially cost-eﬀective solution to
weight management in type 2 diabetes [9].
Intentional weight loss in people with diabetes is very
eﬀective at reducing cardiovascular risk. In a systematic
review Aucott et al. (2004) found that people with diabetes
who lost weight intentionally significantly reduced their
mortality risks by 25% with weight loss of 9–13 kg being
most protective [12]. Therefore development and use of
eﬀective weight loss strategies are very important in people
with diabetes.
A number of studies have examined the use of meal
replacements in this context [13–15].
In a study of 57 subjects with type 2 diabetes comparing
meal replacements with an exchange diet plan for 12 weeks
Yip et al. (2001) [13] found that weight loss in the two
meal replacement groups were greater (6.4% and 6.7%, resp.)
compared with weight loss in the diet plan group (4.9%)
although this was not significant. In addition, fasting glucose,
total cholesterol, and low-density lipoprotein cholesterol
levels were reduced in the meal replacement groups and
the glucose change was significant compared with the diet
plan group (P = 0.01), but HbA1c was not diﬀerent (0.2%
diﬀerence between groups). Similarly Li et al. (2005) [14]
in a longer 12-month study found that percentage weight
loss was greater in the meal replacement group (4.6%) than
in diet plan group (2.3%) although BMI change was not
significant (P = 0.07). Fasting glucose was reduced in meal
replacements group at 6 months and HbA1c level improved
in MR at 6 months compared to the diet plan group by
0.49% (P = 0.1 for comparison), but this diﬀerence had
disappeared by 12 months (0.15%, P = 0.6) and neither
group had a significant change in HbA1c compared to
baseline. Each participant in both groups received individual
consultation with a registered dietitian at baseline, weeks
2, 4, 6, 8 and then monthly for the duration of the 1-year
study and 77 out of 104 subjects completed the study. More
subjects in meal replacements group reduced their use of
medications. In a study of 119 subjects Cheskin et al. (2008)
found that weight loss on a meal replacement program
for 34 weeks with 1-year followup was greater than on a
standard diet with more subjects 40% versus 12% achieving
≥5% weight loss [16]. Dropout was very large with only 48
completing 34 weeks and 33 completing 86 weeks. HbA1c
dropped by 0.28% in the MR group versus an increase of
0.32% in the standard diet (P = 0.06). These HbA1c results
are very similar to ours as were the changes in medication
with seven more individuals reducing drugs in theMR group
than in the SD group. Dosage increases were similar in
both groups. In a report by Ditschuneit (2006) patients with
diabetes on a meal replacement program achieved weight
loss of 5.2% and 4.4% of their body weight at 6 and 12
months, respectively, [15]. In comparison patients on a diet
plan achieved weight loss of 2.9% and 2.4% at 6 and 12
months. All these studies involved a dietitian in the program
delivery.
It would appear that the immediate reduction in carbo-
hydrate using the protein-rich meal replacements was the
most important cause of a fall in HbA1c at 3 months in the
MR group while the 2 kg weight loss in the DB group was
not large enough or had not been present for long enough
to change HbA1c. The regain of some of the lost weight as
well as the reduction to one MR sachet per day may be the
reason for the rise in HbA1c in the MR group at 6 months
and lack of diﬀerence between the 2 groups at this time point.
Medication dosage reduction clearly had an eﬀect on the
results as well, particularly in the MR group. The changes
in HbA1c are very comparable with the published literature.
Greater weight loss is required to maintain the early changes
in HbA1c.
In conclusion use of meal replacements for 6 months can
increase weight loss by 2.5 kg compared with nonprofessional
advice from a diet book, but HbA1c was not significantly
diﬀerent between the groups. In order to achieve a greater
reduction in HbA1c professional advice is probably required,
although this is not a guarantee of success as the Li study
showed no significant eﬀect on HbA1c at 12 months in either
group despite extensive professional advice.
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